Peter Zerhouni new CEO of InDex
This article was originally published in Scrip
InDex Pharmaceuticals has named Peter Zerhouni its new CEO. Mr Zerhouni joins the company, which is developing lead product Kappaproct as a treatment of severe ulcerative colitis, from Diamyd Medical where he was also CEO. He succeeds Jesper Wiklund, who led the company since 2011.